Jpad-Journal of Prevention of Alzheimers Disease最新文献

{"title":"Comparing the Standard and Electronic Versions of the Alzheimer’s Disease Assessment Scale — Cognitive Subscale: A Validation Study","authors":"Todd M. Solomon, J. Barbone, H. T. Feaster, David S. Miller, Guy B. deBros, Cynthia A. Murphy, D. Michalczuk","doi":"10.14283/jpad.2019.27","DOIUrl":"https://doi.org/10.14283/jpad.2019.27","url":null,"abstract":"The Alzheimer’s Disease Assessment Scale (ADAS-Cog) has become the de facto gold-standard for assessing the efficacy of putative anti-dementia treatments. There has been an increasing interest in providing greater standardization, automation, and administration consistency to the scale. Recently, electronic versions of the ADAS-Cog (eADAS-Cog) have been utilized in clinical trials and demonstrated significant reductions in frequency of rater error as compared to paper. In order to establish validity of the electronic version (eADAS-Cog), 20 subjects who had received a diagnosis of probable Alzheimer’s disease (AD) at a private US Memory Clinic completed a single-center, randomized, counterbalanced, prospective trial comparing a version of the eADAS-Cog to the standard paper scale. Interclass Correlation Coefficient on total scores and Kappa analysis on domain scores yielded high agreement (0.88–0.99). Effects of order and mode of administration on ADAS-Cog total scores did not demonstrate a significant main effect. Overall, this study establishes adequate concurrent validity between the ADAS-Cog and eADAS-Cog among an adult population with diagnosed AD.","PeriodicalId":48606,"journal":{"name":"Jpad-Journal of Prevention of Alzheimers Disease","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.14283/jpad.2019.27","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66893284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuropsychological, Psychiatric, and Functional Correlates of Clinical Trial Enrollment","authors":"D. Hammers, Norman L. Foster, J. Hoffman, T. Greene, Kevin Duff","doi":"10.14283/jpad.2019.38","DOIUrl":"https://doi.org/10.14283/jpad.2019.38","url":null,"abstract":"Screen failure rates in Alzheimer’s disease (AD) clinical trial research are unsustainable, with participant recruitment being a top barrier to AD research progress. The purpose of this project was to understand the neuropsychological, psychiatric, and functional features of individuals who failed screening measures for AD trials. Previously collected clinical data from 38 patients (aged 50–83) screened for a specific industry-sponsored clinical trial of MCI/early AD (Biogen 221AD302, [EMERGE]) were analyzed to identify predictors of AD trial screen pass/fail status. Worse performance on non-memory cognitive domains like crystalized knowledge, executive functioning, and attention, and higher self-reported anxiety, was associated with failing the screening visit for the EMERGE AD clinical trial, whereas we were not able to detect a relationship between screening status and memory performance, self-reported depression, or self-reported daily functioning. By identifying predictors of AD trial screen passing/failure, this research may influence decision-making about which patients are most likely to successfully enroll in a trial, thereby potentially lowering participant burden, maximizing study resources, and reducing costs.","PeriodicalId":48606,"journal":{"name":"Jpad-Journal of Prevention of Alzheimers Disease","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.14283/jpad.2019.38","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66893480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Evaluation of Cognitive Health and Related Factors in Elderly at Risk for Developing Alzheimer’s Dementia: A Longitudinal Cohort Study","authors":"C. Udeh-Momoh, G. Price, M. Ropacki, N. Ketter, T. Andrews, H. Arrighi, H. Brashear, Catherine E. Robb, Darina T Bassil, M. Cohn, L. Curry, B. Su, D. Perera, P. Giannakopoulou, J. Car, Heather A. Ward, R. Perneczky, R. Perneczky, R. Perneczky, G. Novak, L. Middleton","doi":"10.14283/jpad.2019.31","DOIUrl":"https://doi.org/10.14283/jpad.2019.31","url":null,"abstract":"BackgroundThe CHARIOT PRO Main study is a prospective, non-interventional study evaluating cognitive trajectories in participants at the preclinical stage of Alzheimer’s disease (AD) classified by risk levels for developing mild cognitive impairment due to AD (MCI-AD).ObjectivesThe study aimed to characterize factors and markers influencing cognitive and functional progression among individuals at-risk for developing MCI-AD, and examine data for more precise predictors of cognitive change, particularly in relation to APOE ε4 subgroup.DesignThis single-site study was conducted at the Imperial College London (ICL) in the United Kingdom. Participants 60 to 85 years of age were classified as high, medium (amnestic or non-amnestic) or low risk for developing MCI-AD based on RBANS z-scores. A series of clinical outcome assessments (COAs) on factors influencing baseline cognitive changes were collected in each of the instrument categories of cognition, lifestyle exposure, mood, and sleep. Data collection was planned to occur every 6 months for 48 months, however the median follow-up time was 18.1 months due to early termination of study by the sponsor.Results987 participants were screened, among them 690 participants were actively followed-up post baseline, of whom 165 (23.9%) were APOE ε4 carriers; with at least one copy of the allele. The mean age was 68.73 years, 94.6% were white, 57.4% were female, and 34.8% had a Family History of Dementia with a somewhat larger percentage in the APOE ε4 carrier group (42.4%) compared to the non-carrier group (32.4%). Over half of the participants were married and 53% had a Bachelor’s or higher degree. Most frequently, safety events typical for this population consisted of upper respiratory tract infection (10.4%), falls (5.2%), hypertension (3.5%) and back pain (3.0%).Conclusion (clinical relevance)AD-related measures collected during the CHARIOT PRO Main study will allow identification and evaluation of AD risk factors and markers associated with cognitive performance from the pre-clinical stage. Evaluating the psycho-biological characteristics of these pre-symptomatic individuals in relation to their natural neurocognitive trajectories will enhance current understanding on determinants of the initial signs of cognitive changes linked to AD.","PeriodicalId":48606,"journal":{"name":"Jpad-Journal of Prevention of Alzheimers Disease","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.14283/jpad.2019.31","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66893113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symposia","authors":"A. Lo, C. D. Evans, Michele Mancini, Qun-Fu Lin, Hong Wang, Peng Liu, Sergey, Shcherbinin, Ming Lu, Arnaud Charil, B. A. Willis, Michael, Irizarry, Robert Alexander, Daniel K. Burns, K. Welsh-Bohmer, Carl Chiang, Meredith Culp, J. O’neil, B.L. Plassman, Craig, Metz, Deborah Yarbrough, Jingtao Wu, R. Evans, Kumar Budur, Stephen K. Brannan, Ann M. Saunders, Emiliangelo Ratti","doi":"10.14283/jpad.2018.39","DOIUrl":"https://doi.org/10.14283/jpad.2018.39","url":null,"abstract":"Introduction: The amyloid hypothesis proposes that Aβ peptides are intimately involved in the etiology of Alzheimer’s disease (AD) via their aggregation to form toxic complexes that lead to neurodegeneration. Aβ is produced via sequential proteolytic cleavage of the parent molecule, amyloid precursor protein, by β-secretase (BACE1) followed by γ-secretase. Inhibition of BACE1 is a potential novel therapeutic strategy for slowing or halting progression of AD by reducing Aβ production. This approach differs from previous anti-amyloid approaches using monoclonal antibodies to clear Aβ. In the first large-scale clinical trial (EPOCH) of a BACE1 inhibitor, verubecestat doses of 12 mg and 40 mg were ineffective at slowing the rate of cognitive or functional decline over 78 weeks in participants with clinically diagnosed mild-to-moderate AD, despite reducing cerebrospinal fluid (CSF) Aβ levels by 63-81% (Egan et al. NEJM 2018;378:1691-1703). One interpretation of these findings is that treatment at the AD dementia stage is too late in the disease process. A second large trial (APECS; clinicaltrials.gov NCT01953601) was initiated in 2013 to evaluate verubecestat in participants with prodromal AD. Eligible participants had subjective memory decline with objective memory impairment and were amyloid positive (determined by amyloid imaging PET scan or CSF tau: Aβ42 ratio) but did not meet criteria for dementia. A decision to terminate the APECS trial was made in February 2018 following a recommendation by the external Data Monitoring Committee, which concluded that it was unlikely that positive benefit/risk could be established if the trial continued to its scheduled completion in 2019. Objectives: The objectives of this symposium are to present key efficacy and safety findings from the APECS trial and to have a panel of experts discuss the findings and implications for future development of BACE1 inhibitors. Results will be unveiled at CTAD. Discussion: The findings from the APECS trial suggest that blocking Aβ production at the prodromal AD stage does not slow clinical progression. Because the deposition of Aβ takes place years before the prodromal stage, it is possible that administration of an antiamyloid agent like verubecestat may be effective if given even earlier in the disease process. An alternative possibility is that the production of Aβ peptides may not play a major causal role in the pathophysiology of AD. Conclusions: Verubecestat was not effective in slowing clinical progression in participants with prodromal AD.","PeriodicalId":48606,"journal":{"name":"Jpad-Journal of Prevention of Alzheimers Disease","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.14283/jpad.2018.39","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66893385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force","authors":"Mary Sano, M. Soto, M. Carrillo, J. Cummings, S. Hendrix, J. Mintzer, A. Porsteinsson, P. Rosenberg, L. Schneider, J. Touchon, P. Aisen, B. Vellas, C. Lyketsos, Euusctad Task Force members","doi":"10.14283/jpad.2018.15","DOIUrl":"https://doi.org/10.14283/jpad.2018.15","url":null,"abstract":"For the second time in the past 3 years, the EU-US CTAD Task Force addressed challenges related to designing clinical trials for agitation in dementia, which is one of the most disruptive aspects of the condition for both patients and caregivers. Six recommendations emerged from the Task Force meeting: 1 – Operationalizing agitation criteria established by the IPA; 2 – Combining clinician- and caregiver-derived outcomes as primary outcome measures; 3 – Using global ratings to define clinically meaningful effects and power studies; 4 – Improving the accuracy of caregiver reports by better training and education of caregivers; 5 – Employing emerging technologies to collect near real-time behavioral data; and 6 – Utilizing innovative trial designs and increasing the use of biomarkers to maximize the productivity of clinical trials for neuropsychiatric symptoms.","PeriodicalId":48606,"journal":{"name":"Jpad-Journal of Prevention of Alzheimers Disease","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.14283/jpad.2018.15","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66893315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Posters","authors":"N. Falgàs, R. Sánchez-Valle, Mircea, Balasa, S. Borrego, Magdalena Castellví, -. AdriàTort, Merino, J. Olives, B. Bosch, Guadalupe Fernández, F. Lomeña, N. Bargalló, Albert Lladó, Itziar, D. Rojas, J. Romero, O. Rodríguez‐Gomez, P. Pesini, Á. Sanabria, A. Pérez-Cordón, Carla, Abdelnour, M. Rosende-Roca, Ana, Mauléon, Liliana Vargas, Montserrat Alegret, A. Espinosa, G. Ortega, Silvia Gil, M. Guitart, Anna Gailhajane, M. Santos-Santos, S. Moreno-Grau, Oscar, Sotolongo-Grau, S. Ruiz, L. Montrreal, Elvira, Martín, E. Pelejà, F. Lomeña, F. Campos, A. Vivas, M. Gómez-Chiari, M. A. Tejero, J. Giménez, V. Pérez-Grijalba, Marta Marquié, G. Monté-Rubio, Sergi Valero, A. Orellana, Lluís., Tárraga, Manuel E. Sarasa, A. Ruiz, Mercè Boada","doi":"10.14283/jpad.2018.40","DOIUrl":"https://doi.org/10.14283/jpad.2018.40","url":null,"abstract":"P21: PATTERNS OF MMSE SUBTEST SCORES IN AMYLOID-POSITIVE AND -NEGATIVE PARTICIPANTS IN J-ADNI. Ryoko Ihara1, Kazushi Suzuki1, Atsushi Iwata2, Takeshi Iwatsubo1,3, the Japanese Alzheimer’s Disease Neuroimaging Initiative ((1) The Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo Japan; (2) Department of Neurology, The University of Tokyo, Tokyo Japan; (3) Department of Neuropathology, The University of Tokyo, Tokyo – Japan)","PeriodicalId":48606,"journal":{"name":"Jpad-Journal of Prevention of Alzheimers Disease","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.14283/jpad.2018.40","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66893032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Vascular Neuropathology on Late-life Cognition: Results from the SMART Project.","authors":"R. Kryscio, E. Abner, Peter T. Nelson, David A. Bennett, J. Schneider, Lei Yu, L. Hemmy, K. Lim, Kamal Masaki, N. Cairns, C. Xiong, R. Woltjer, H. Dodge, S. Tyas, D. Fardo, W. Lou, L. Wan, F. Schmitt","doi":"10.14283/JPAD.2016.95","DOIUrl":"https://doi.org/10.14283/JPAD.2016.95","url":null,"abstract":"BACKGROUND\u0000Cerebral vascular pathology may contribute to cognitive decline experienced by some elderly near death. Given evidence for mixed neuropathologies in advanced age, preventing or reducing cerebrovascular burden in late life may be beneficial.\u0000\u0000\u0000OBJECTIVE\u0000To correlate measures of cerebral vascular pathology with cognitive trajectories.\u0000\u0000\u0000SETTING\u0000Observational study.\u0000\u0000\u0000PARTICIPANTS\u0000A cohort of 2,274 individuals who came to autopsy at a mean age of 89.3 years and 82 percent of whom had at least two cognitive assessments within the last six years of life was compiled from six centers conducting longitudinal studies.\u0000\u0000\u0000MEASUREMENTS\u0000For each cognitive domain: immediate and delayed memory, language, and naming, three trajectories were examined: good, intermediate, and poor cognition. The probability of a participant belonging to each trajectory was associated with measures of cerebral vascular pathology after adjustment for demographics, APOE, and Alzheimer neuropathology.\u0000\u0000\u0000RESULTS\u0000A large proportion of the cohort (72-94%) experienced good or intermediate cognition in the four domains examined. The presence of arteriolosclerosis and the presence of lacunar infarcts doubled the odds of belonging to the poor cognitive trajectory for language when compared to the good trajectory. The presence of lacunar infarcts increased the odds of an intermediate or poor trajectory for immediate and delayed recall while the presence of large artery infarcts increased the odds of poor trajectories for all four cognitive domains examined. Microinfarcts and cerebral amyloid angiopathy had little effect on the trajectories.\u0000\u0000\u0000CONCLUSION\u0000Indicators of cerebral vascular pathology act differently on late life cognition.","PeriodicalId":48606,"journal":{"name":"Jpad-Journal of Prevention of Alzheimers Disease","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66892622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials.","authors":"D. Rentz, M. Dekhtyar, J. Sherman, S. Burnham, D. Blacker, Sarah L. Aghjayan, K. Papp, R. Amariglio, A. Schembri, Tanya Chenhall, P. Maruff, P. Aisen, B. Hyman, R. Sperling","doi":"10.14283/JPAD.2015.78","DOIUrl":"https://doi.org/10.14283/JPAD.2015.78","url":null,"abstract":"BACKGROUND\u0000Technological advances now make it feasible to administer cognitive assessments at-home on mobile and touch-screen devices such as an iPad or tablet computer. Validation of these techniques is necessary to assess their utility in clinical trials.\u0000\u0000\u0000OBJECTIVES\u0000We used a Computerized Cognitive Composite for Preclinical Alzheimer's Disease (C3-PAD) developed for iPad 1) to determine the feasibility of performing the C3-PAD at home by older individuals without the presence of a trained psychometrician; 2) to explore the reliability of in-clinic compared to at-home C3-PAD performance and 3) to examine the comparability of C3-PAD performance to standardized neuropsychological tests.\u0000\u0000\u0000DESIGN SETTING PARTICIPANTS\u0000Forty-nine cognitively normal older individuals (mean age, 71.467.7 years; 20% non-Caucasian) were recruited from research centers at the Massachusetts General Hospital and Brigham and Women's Hospital. Participants made two in-clinic visits one-week apart and took five 30-minute alternate versions of the C3-PAD at-home measuring episodic memory, reaction time and working memory.\u0000\u0000\u0000MEASUREMENTS\u0000A reliability analysis explored equivalence of the six alternate C3-PAD test versions. A feasibility assessment calculated the percentage of individuals who completed all at-home tests correctly, in contrast to incomplete assessments. Correlational analyses examined the association between C3-PAD-clinic compared to C3-PAD-home assessments and between C3-PAD performance and standardized paper and pencil tests.\u0000\u0000\u0000RESULTS\u0000Excellent reliability was observed among the 6 C3-PAD alternate versions (Cronbach alpha coefficient=0.93). A total of 28 of 49 participants completed all at-home sessions correctly and 48 of 49 completed four out of five correctly. There were no significant differences in participant age, sex or education between complete and incomplete at-home assessments. A single in-clinic C3-PAD assessment and the at-home C3-PAD assessments were highly associated with each other (r2=0.508, p<0.0001), suggesting that at-home tests provide reliable data as in-clinic assessments. There was also a moderate association between the at-home C3-PAD assessments and the in-clinic standardized paper and pencil tests covering similar cognitive domains (r2= 0.168, p< 0.003).\u0000\u0000\u0000CONCLUSIONS\u0000Reliable and valid cognitive data can be obtained from the C3-PAD assessments in the home environment. With initial in-clinic training, a high percentage of older individuals completed at-home assessments correctly. At-home cognitive testing shows promise for inclusion into clinical trial designs.","PeriodicalId":48606,"journal":{"name":"Jpad-Journal of Prevention of Alzheimers Disease","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66892506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary Factors and Cognitive Decline.","authors":"P J Smith, J A Blumenthal","doi":"10.14283/jpad.2015.71","DOIUrl":"10.14283/jpad.2015.71","url":null,"abstract":"<p><p>Cognitive decline is an increasingly important public health problem, with more than 100 million adults worldwide projected to develop dementia by 2050. Accordingly, there has been an increased interest in preventive strategies that diminish this risk. It has been recognized that lifestyle factors including dietary patterns, may be important in the prevention of cognitive decline and dementia in later life. Several dietary components have been examined, including antioxidants, fatty acids, and B vitamins. In addition, whole dietary eating plans, including the Mediterranean diet (MeDi), and the Dietary Approaches to Stop Hypertension (DASH) diet, with and without weight loss, have become areas of increasing interest. Although prospective epidemiological studies have observed that antioxidants, fatty acids, and B vitamins are associated with better cognitive functioning, randomized clinical trials have generally failed to confirm the value of any specific dietary component in improving neurocognition. Several randomized trials have examined the impact of changing 'whole' diets on cognitive outcomes. The MeDi and DASH diets offer promising preliminary results, but data are limited and more research in this area is needed.</p>","PeriodicalId":48606,"journal":{"name":"Jpad-Journal of Prevention of Alzheimers Disease","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66892941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SHORT-TERM IMPACT OF A COMBINED NUTRACEUTICAL ON COGNITIVE FUNCTION, PERCEIVED STRESS AND DEPRESSION IN YOUNG ELDERLY WITH COGNITIVE IMPAIRMENT: A PILOT, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL","authors":"A. Cicero, M. Bove, A. Colletti, M. Rizzo, F. Fogacci, M. Giovannini, C. Borghi","doi":"10.14283/jpad.2016.110","DOIUrl":"https://doi.org/10.14283/jpad.2016.110","url":null,"abstract":"Background: The prevalence of senile dementia is increasing worldwide, especially in the developed countries. Nevertheless, drug therapy isn’t often enough to treat this condition. Researchers are evaluating the possible impact of a preventive approach, based on an improvement of lifestyle and the intake of micronutrients. Moreover, there is an increasing interest for combined nutraceuticals that can act as memory and learning enhancers, with a significant and beneficial potential on the cognitive disorders. Objective: To evaluate the effects of a rational assemblage of nutraceuticals on cognitive functions in a sample of 30 elderly subjects. Design: Double bind, cross-over designed trial versus placebo Setting: outpatient clinical practice Participants: 30 elderly subjects with basal Mini-Mental State Examination score between 20 and 27 and self-perceived cognitive decline. Intervention: Treatment with a combination of nutraceuticals based on Bacopa monnieri, L-theanine, Crocus sativus, copper, folate and vitamins of B and D group. After2 months of treatment or placebo. Measurements: Patients were evaluated with Mini-Mental State Examination (MMSE), Perceived Stress Questionnaire (PSQ) and Index and Self-Rating Depression Scale (SRDS). Results: MMSE and PSQ Index significantly improved in the active treatment arm, both versus baseline and versus the parallel arm. Both groups experienced a significant improving in the SRDS scores. Conclusions: We obtained a good and significant improvement of the cognitive functions tested with the MMSE, PSQ-Index and SRDS score, after 2 months of combined therapy of nutraceuticals. Further confirmation will be needed to verify these observations on the middle and long term in a larger number of subjects.","PeriodicalId":48606,"journal":{"name":"Jpad-Journal of Prevention of Alzheimers Disease","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66892613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}